GLP-1 medications help with weight loss by acting on areas of the brain that regulate appetite and satiety, while also slowing the rate at which food leaves the stomach
other countries, food supply and consumption, mental health and SSRI / stimulant prescription prevalence, and other lifestyle factors
Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts
According to FDA prescribing information, these include: Nausea (occurring in 1544% of patients depending on the specific agent and dose) Vomiting (524% of patients) Diarrhea (821% of patients) Constipation (1024% of patients) Abdominal pain or discomfort (514% of patients) These symptoms typically emerge during dose initiation or escalation and often diminish over several weeks as the body adapts
Regulatory Retatrutides approval hinges on a complicated regulatory environment
Injectable GLP-1 medications require weekly or twice-weekly subcutaneous administration, making injection-site tolerability a genuine quality-of-life concern
